Identification of novel radiosensitizers in a high-throughput, cell-based screen for DSB repair inhibitors

Molecular Cancer Therapeutics

Volumn 14, Issue 2, 2015, Pages 326-342

  Goglia, Alexander G ^a   Delsite, Robert ^a   Luz, Antonio N ^b   Shahbazian, David ^c   Salem, Ahmed F ^d   Sundaram, Ranjini K ^d   Chiaravalli, Jeanne ^b   Hendrikx, Petrus J ^a   Wilshire, Jennifer A ^a   Jasin, Maria ^a   Kluger, Harriet M ^c   Glickman, J Fraser ^b   Powell, Simon N ^a   Bindra, Ranjit S ^d  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

^c YALE CANCER CENTER   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 ETHYLPHENOXY) 3 (1,2,3,4 TETRAHYDRO 1 NAPHTHYLAMINO) 2 PROPANOL OXALATE; AGENTS AFFECTING CELL DIVISION; ANTINEOPLASTIC AGENT; CYPROTERONE; DOUBLE STRAND BREAK REPAIR INHIBITOR; ETOPOSIDE; LOPERAMIDE; MIBEFRADIL; N,N' DIBENZHYDRYLETHYLENEDIAMINE; PIMOZIDE; RADIOSENSITIZING AGENT; UNCLASSIFIED DRUG; GREEN FLUORESCENT PROTEIN; MOLECULAR LIBRARY;

ADHERENT CELL; ARTICLE; CANCER CELL LINE; CELL COUNT; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DNA CLEAVAGE; DNA END JOINING REPAIR; DOUBLE STRANDED DNA BREAK; DRUG CYTOTOXICITY; DRUG SCREENING; GLIOBLASTOMA; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MOLECULAR LIBRARY; NUCLEAR LOCALIZATION SIGNAL; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIZATION; RECOMBINATION REPAIR; DNA REPAIR; DRUG EFFECTS; HOMOLOGOUS RECOMBINATION; METABOLISM; PHARMACOLOGY; PILOT STUDY; PROCEDURES; REPRODUCIBILITY; TUMOR CELL LINE;

CELL LINE, TUMOR; DNA BREAKS, DOUBLE-STRANDED; DNA REPAIR; DRUG SCREENING ASSAYS, ANTITUMOR; GREEN FLUORESCENT PROTEINS; HIGH-THROUGHPUT SCREENING ASSAYS; HOMOLOGOUS RECOMBINATION; HUMANS; PILOT PROJECTS; RADIATION-SENSITIZING AGENTS; REPRODUCIBILITY OF RESULTS; SMALL MOLECULE LIBRARIES;

EID: 84923325339     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-0765     Document Type: Article

References (80)

1. Smith-Roe SL, Patel SS, Zhou Y, Simpson DA, Rao S, Ibrahim JG, et al. Separation of intra-S checkpoint protein contributions to DNA replication fork protection and genomic stability in normal human fibroblasts. Cell Cycle 2013;12:332-45.
2. Kaufmann WK, Anderson CW. Compensation, crosstalk and sequestering: the currency of checkpoints in cancer. Cell Cycle 2013;12:1163-4.
3. Morandell S, Yaffe MB. Exploiting synthetic lethal interactions between DNA damage signaling, checkpoint control, and p53 for targeted cancer therapy. Prog Mol Biol Transl Sci 2012;110:289-314.
4. Kaufmann WK. Cell cycle checkpoints and DNA repair preserve the stability of the human genome. Cancer Metastasis Rev 1995;14:31-41.
5. Thoms J, Bristow RG. DNA repair targeting and radiotherapy: a focus on the therapeutic ratio. Semin Radiat Oncol 2010;20:217-22.
6. Senra JM, Telfer BA, Cherry KE, McCrudden CM, Hirst DG, O'Connor MJ, et al. Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft. Mol Cancer Ther 2011;10:1949-58.
7. 2 checkpoint and inhibition of homologous recombinational DNA repair. Cancer Res 2010;70:4972-81.
8. Tavecchio M, Munck JM, Cano C, Newell DR, Curtin NJ. Further characterisation of the cellular activity of the DNA-PK inhibitor, NU7441, reveals potential cross-talk with homologous recombination. Cancer Chemother Pharmacol 2012;69:155-64.
9. Schenone M, Dancik V, Wagner BK, Clemons PA. Target identi fication and mechanism of action in chemical biology and drug discovery. Nat Chem Biol 2013;9:232-40.
10. Ciccia A, Elledge SJ. The DNA damage response: making it safe to play with knives. Mol Cell 2010;40:179-204.
11. 2 phase. EMBO J 2011;30:1079-92.
12. Frit P, Barboule N, Yuan Y, Gomez D, Calsou P. Alternative end-joining pathway(s): bricolage at DNA breaks. DNA Repair 2014;17:81-97.
13. Lieber MR. The mechanism of human nonhomologous DNA end joining. J Biol Chem 2008;283:1-5.
14. Corneo B, Wendland RL, Deriano L, Cui X, Klein IA, Wong SY, et al. Rag mutations reveal robust alternative end joining. Nature 2007;449:483-6.
15. Guirouilh-Barbat J, Rass E, Plo I, Bertrand P, Lopez BS. Defects in XRCC4 and KU80 differentially affect the joining of distal nonhomologous ends. Proc Natl Acad Sci U S A 2007;104:20902-7.
16. Soulas-Sprauel P, Le Guyader G, Rivera-Munoz P, Abramowski V, Olivier-Martin C, Goujet-Zalc C, et al. Role for DNA repair factor XRCC4 in immunoglobulin class switch recombination. J Exp Med 2007;204:1717-27.
17. Yan CT, Boboila C, Souza EK, Franco S, Hickernell TR, Murphy M, et al. IgH class switching and translocations use a robust non-classical end-joining pathway. Nature 2007;449:478-82.
18. Xie A, Kwok A, Scully R. Role of mammalian Mre11 in classical and alternative nonhomologous end joining. Nat Struct Mol Biol 2009;16:814-8.
19. Wang M, Wu W, Wu W, Rosidi B, Zhang L, Wang H, et al. PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways. Nucleic Acids Res 2006;34:6170-82.
20. Saribasak H, Maul RW, Cao Z, McClure RL, Yang W, McNeill DR, et al. XRCC1 suppresses somatic hypermutation and promotes alternative nonhomologous end joining in Igh genes. J Exp Med 2011;208:2209-16.
21. Caldecott KW, Tucker JD, Stanker LH, Thompson LH. Characterization of the XRCC1-DNA ligase III complex in vitro and its absence from mutant hamster cells. Nucleic Acids Res 1995;23:4836-43.
22. Han L, Mao W, Yu K. X-ray repair cross-complementing protein 1 (XRCC1) de ficiency enhances class switch recombination and is permissive for alternative end joining. Proc Natl Acad Sci U S A 2012;109:4604-8.
23. Boboila C, Oksenych V, Gostissa M, Wang JH, Zha S, Zhang Y, et al. Robust chromosomal DNA repair via alternative end-joining in the absence of X-ray repair cross-complementing protein 1 (XRCC1). Proc Natl Acad Sci U S A 2012;109:2473-8.
24. Simsek D, Furda A, Gao Y, Artus J, Brunet E, Hadjantonakis AK, et al. Crucial role for DNA ligase III in mitochondria but not in Xrcc1-dependent repair. Nature 2011;471:245-8.
25. Symington LS, Gautier J. Double-strand break end resection and repair pathway choice. Annu Rev Genet 2011;45:247-71.
26. Lee K, Lee SE. Saccharomyces cerevisiae Sae2- and Tel1-dependent single-strand DNA formation at DNA break promotes microhomology-mediated end joining. Genetics 2007;176:2003-14.
27. Bindra RS, Goglia AG, Jasin M, Powell SN. Development of an assay to measure mutagenic non-homologous end-joining repair activity in mammalian cells. Nucleic Acids Res 2013;41:e115.
28. Lin FL, Sperle K, Sternberg N. Model for homologous recombination during transfer of DNA into mouse L cells: role for DNA ends in the recombination process. Mol Cell Biol 1984;4:1020-34.
29. Martin NT, Nahas SA, Tunuguntla R, Fike F, Gatti RA. Assessing 'radio-sensitivity' with kinetic profiles of gamma-H2AX, 53BP1 and BRCA1 foci. Radiother Oncol 2011;101:35-8.
30. Banath JP, Macphail SH, Olive PL. Radiation sensitivity, H2AX phosphorylation, and kinetics of repair of DNA strand breaks in irradiated cervical cancer cell lines. Cancer Res 2004;64:7144-9.
31. Kent CR, Eady JJ, Ross GM, Steel GG. The comet moment as a measure of DNA damage in the comet assay. Int J Radiat Biol 1995;67:655-60.
32. Weingeist DM, Ge J, Wood DK, Mutamba JT, Huang Q, Rowland EA, et al. Single-cell microarray enables high-throughput evaluation of DNA double-strand breaks and DNA repair inhibitors. Cell Cycle 2013;12:907-15.
33. Pierce AJ, Johnson RD, Thompson LH, Jasin M. XRCC3 promotes homology-directed repair of DNA damage in mammalian cells. Genes Dev 1999;13:2633-8.
34. Truong LN, Li Y, Shi LZ, Hwang PY, He J, Wang H, et al. Microhomology-mediated end joining and homologous recombination share the initial end resection step to repair DNA double-strand breaks in mammalian cells. Proc Natl Acad Sci U S A 2013;110:7720-5.
35. Bennardo N, Cheng A, Huang N, Stark JM. Alternative-NHEJ is a mechanistically distinct pathway of mammalian chromosome break repair. PLoS Genet 2008;4:e1000110.
36. Bennardo N, Stark JM. ATM limits incorrect end utilization during nonhomologous end joining of multiple chromosome breaks. PLoS Genet 2010;6:e1001194.
37. Willers H, Husson J, Lee LW, Hubbe P, Gazemeier F, Powell SN, et al. Distinct mechanisms of nonhomologous end joining in the repair of sitedirected chromosomal breaks with noncomplementary and complementary ends. Radiat Res 2006;166:567-74.
38. Hartlerode A, Odate S, Shim I, Brown J, Scully R. Cell cycle-dependent induction of homologous recombination by a tightly regulated I-SceI fusion protein. PLoS ONE 2011;6:e16501.
39. Lundholt BK, Scudder KM, Pagliaro L. Asimple technique for reducing edge effect in cell-based assays. J Biomol Screen 2003;8:566-70.
40. Black CB, Duensing TD, Trinkle LS, Dunlay RT. Cell-based screening using high-throughput flow cytometry. Assay Drug Dev Technol 2011;9:13-20.
41. Munshi A, Hobbs M, Meyn RE. Clonogenic cell survival assay. Methods Mol Med 2005;110:21-8.
42. Soutoglou E, Dorn JF, Sengupta K, Jasin M, Nussenzweig A, Ried T, et al. Positional stability of single double-strand breaks inmammalian cells. Nat Cell Biol 2007;9:675-82.
43. Torrance CJ, Agrawal V, Vogelstein B, Kinzler KW. Use of isogenic human cancer cells for high-throughput screening and drug discovery. Nat Biotechnol 2001;19:940-5.
44. Zhang JH, Chung TD, Oldenburg KR. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999;4:67-73.
45. Dupre A, Boyer-Chatenet L, Sattler RM, Modi AP, Lee JH, Nicolette ML, et al. A forward chemical genetic screen reveals an inhibitor of the Mre11-Rad50-Nbs1 complex. Nat Chem Biol 2008;4:119-25.
46. Korn K, Krausz E. Cell-based high-content screening of small-molecule libraries. Curr Opin Chem Biol 2007;11:503-10.
47. Fattah F, Lee EH, Weisensel N, Wang Y, Lichter N, Hendrickson EA. Ku regulates the non-homologous end joining pathway choice of DNA double-strand break repair in human somatic cells. PLoS Genet 2010;6:e1000855.
48. Baell JB, Holloway GA. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J Med Chem 2010;53:2719-40.
49. Shi LM, Fan Y, Lee JK, Waltham M, Andrews DT, Scherf U, et al. Mining and visualizing large anticancer drug discovery databases. J Chem Inf Comput Sci 2000;40:367-79.
50. Mansour WY, Rhein T, Dahm-Daphi J. The alternative end-joining pathway for repair of DNA double-strand breaks requires PARP1 but is not dependent upon microhomologies. Nucleic Acids Res 2010;38:6065-77.
51. Mansour WY, Schumacher S, Rosskopf R, Rhein T, Schmidt-Petersen F, Gatzemeier F, et al. Hierarchy of nonhomologous end-joining, single-strand annealing and gene conversion at site-directed DNA double-strand breaks. Nucleic Acids Res 2008;36:4088-98.
52. Schulte-Uentrop L, El-Awady RA, Schliecker L, Willers H, Dahm-Daphi J. Distinct roles of XRCC4 and Ku80 in non-homologous end-joining of endonuclease- and ionizing radiation-induced DNA double-strand breaks. Nucleic Acids Res 2008;36:2561-9.
53. Allen C, Halbrook J, Nickoloff JA. Interactive competition between homologous recombination and non-homologous end joining. Mol Cancer Res 2003;1:913-20.
54. Convery E, Shin EK, Ding Q, Wang W, Douglas P, Davis LS, et al. Inhibition of homologous recombination by variants of the catalytic subunit of the DNA-dependent protein kinase (DNA-PKcs). Proc Natl Acad Sci U S A 2005;102:1345-50.
55. Meek K, Douglas P, Cui X, Ding Q, Lees-Miller SP. trans Autophosphorylation at DNA-dependent protein kinase's two major autophosphorylation site clusters facilitates end processing but not end joining. Mol Cell Biol 2007;27:3881-90.
56. Cui X, Yu Y, Gupta S, Cho YM, Lees-Miller SP, Meek K. Autophosphorylation of DNA-dependent protein kinase regulates DNA end processing and may also alter double-strand break repair pathway choice. Mol Cell Biol 2005;25:10842-52.
57. Bunting SF, Callen E, Wong N, Chen HT, Polato F, Gunn A, et al. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell 2010;141:243-54.
58. Matsuoka S, Huang M, Elledge SJ. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science 1998;282:1893-7.
59. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 1998;273:5858-68.
60. Panier S, Boulton SJ. Double-strand break repair: 53BP1 comes into focus. Nat Rev Mol Cell Biol 2014;15:7-18.
61. Pollard JM, Gatti RA. Clinical radiation sensitivity with DNA repair disorders: an overview. Int J Radiat Oncol Biol Phys 2009;74:1323-31.
62. Laperriere N, Zuraw L, Cairncross G. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review. Radiother Oncol 2002;64:259-73.
63. Puck TT, Marcus PI. Action of x-rays on mammalian cells. J Exp Med 1956;103:653-66.
64. Sumantran VN. Cellular chemosensitivity assays: an overview. Methods Mol Biol 2011;731:219-36.
65. Steel GG. The search for therapeutic gain in the combination of radiotherapy and chemotherapy. Radiother Oncol 1988;11:31-53.
66. Shahbazian D, Bindra RS, Kluger HM, Glazer PM. Radiation sensitivity and sensitization in melanoma. Pigment Cell Melanoma Research 2013;26:928-30.
67. Shahar OD, Kalousi A, Eini L, Fisher B, Weiss A, Darr J, et al. A high-throughput chemical screen with FDA approved drugs reveals that the antihypertensive drug Spironolactone impairs cancer cell survival by inhibiting homology directed repair. Nucleic Acids Res 2014;42:5689-701.
68. Jayathilaka K, Sheridan SD, Bold TD, Bochenska K, Logan HL, Weichselbaum RR, et al. A chemical compound that stimulates the human homologous recombination protein RAD51. Proc Natl Acad Sci U S A 2008;105:15848-53.
69. Budke B, Logan HL, Kalin JH, Zelivianskaia AS, Cameron McGuire W, Miller LL, et al. RI-1: a chemical inhibitor of RAD51 that disrupts homologous recombination in human cells. Nucleic Acids Res 2012;40:7347-57.
70. Huang F, Mazina OM, Zentner IJ, Cocklin S, Mazin AV. Inhibition of homologous recombination in human cells by targeting RAD51 recombinase. J Med Chem 2012;55:3011-20.
71. Huang F, Motlekar NA, Burgwin CM, Napper AD, Diamond SL, Mazin AV. Identification of specifi c inhibitors of human RAD51 recombinase using high-throughput screening. ACS Chem Biol 2011;6:628-35.
72. Singh SK, Wu W, Zhang L, Klammer H, Wang M, Iliakis G. Widespread dependence of backup NHEJ on growth state: ramifications for the use of DNA-PK inhibitors. Int J Radiat Oncol Biol Phys 2011;79:540-8.
73. Shope RE. An antiviral substance from Penicillium funiculosum. VII. An attempt to determine whether the material responsible for the antipassive immunity effect exhibited by mice injected with helenine is an interferon. J Exp Med 1966;124:915-9.
74. Knight ZA, Chiang GG, Alaimo PJ, Kenski DM, Ho CB, Coan K, et al. Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold. Bioorg Med Chem 2004;12:4749-59.
75. Sukoff Rizzo SJ, Leonard SK, Gilbert A, Dollings P, Smith DL, Zhang MY, et al. The metabotropic glutamate receptor 7 allosteric modulator AMN082: a monoaminergic agent in disguise? J Pharmacol Exp Ther 2011;338:345-52.
76. Lacinova L. Pharmacology of recombinant low-voltage activated calcium channels. Curr Drug Target CNS Neurol Disord 2004;3:105-11.
77. Egolf A, Coffey BJ. Current pharmacotherapeutic approaches for the treatment of Tourette syndrome. Drugs Today 2014;50:159-79.
78. Keir ST, Friedman HS, Reardon DA, Bigner DD, Gray LA. Mibefradil, a novel therapy for glioblastoma multiforme: cell cycle synchronization and interlaced therapy in a murine model. J Neurooncol 2013;111:97-102.
79. Sheehan JP, Xu Z, Popp B, Kowalski L, Schlesinger D. Inhibition of glioblastoma and enhancement of survival via the use of mibefradil in conjunction with radiosurgery. J Neurosurg 2013;118:830-7.
80. Valerie NC, Dziegielewska B, Hosing AS, Augustin E, Gray LS, Brautigan DL, et al. Inhibition of T-type calcium channels disrupts Akt signaling and promotes apoptosis in glioblastoma cells. Biochem Pharmacol 2013;85:888-97.